Nikko Asset Management Americas’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$108M Sell
5,104,178
-381,975
-7% -$7.64M 1.53% 18
2025
Q4
$89.4M Buy
5,486,153
+109,270
+2% +$1.65M 1.03% 31
2025
Q3
$62.9M Sell
5,376,883
-632,770
-11% -$8.25M 0.61% 43
2025
Q2
$69.5M Buy
6,009,653
+646,997
+12% +$5.9M 0.69% 38
2025
Q1
$46.8M Sell
5,362,656
-350,828
-6% -$4.42M 0.6% 42
2024
Q4
$82M Sell
5,713,484
-659,728
-10% -$10.4M 0.89% 32
2024
Q3
$144M Buy
6,373,212
+224,960
+4% +$4.65M 1.63% 18
2024
Q2
$119M Buy
6,148,252
+2,526,474
+70% +$66.2M 1.38% 23
2024
Q1
$136M Buy
3,621,778
+1,338,248
+59% +$58.8M 1.35% 21
2023
Q4
$128M Buy
2,283,530
+565,059
+33% +$24.6M 1.23% 23
2023
Q3
$70.9M Sell
1,718,471
-47,163
-3% -$2.45M 0.85% 28
2023
Q2
$98.6M Sell
1,765,634
-255,435
-13% -$13.8M 1.04% 25
2023
Q1
$110M Sell
2,021,069
-156,919
-7% -$7.33M 1.26% 22
2022
Q4
$79.4M Sell
2,177,988
-29,270
-1% -$957K 1.14% 23
2022
Q3
$61.1M Buy
2,207,258
+793,419
+56% +$30.2M 0.78% 28
2022
Q2
$56.6M Sell
1,413,839
-17,934
-1% -$930K 0.7% 33
2022
Q1
$109M Buy
1,431,773
+183,813
+15% +$16.1M 0.8% 28
2021
Q4
$166M Sell
1,247,960
-85,584
-6% -$13.1M 0.87% 30
2021
Q3
$192M Sell
1,333,544
-208,044
-13% -$35.7M 0.82% 34
2021
Q2
$299M Buy
1,541,588
+498,675
+48% +$90.2M 1.17% 27
2021
Q1
$189M Buy
1,042,913
+924,534
+781% +$160M 0.92% 35
2020
Q4
$16.8M Buy
118,379
+16,111
+16% +$2.34M 0.1% 108
2020
Q3
$12.2M Sell
102,268
-103,945
-50% -$10.9M 0.11% 103
2020
Q2
$17.8M Buy
+206,213
New +$16.1M 0.23% 65

Other funds holding TXG

Nikko Asset Management Americas's TXG Position: Q1 2026 in Review

Nikko Asset Management Americas reduced its 10x Genomics (TXG) stake by 7% in Q1 2026, selling an estimated $7.64M and leaving 5,104,178 shares worth $108M. The position accounts for 1.53% of the portfolio, ranked #18.

Nikko Asset Management Americas first reported a position in TXG in Q2 2020 and has held it in 24 quarters since. The position peaked at $299M in Q2 2021. 330 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Nikko Asset Management Americas held 5,104,178 shares of 10x Genomics worth $108M as of Q1 2026.
  • Nikko Asset Management Americas sold 381,975 10x Genomics shares in Q1 2026, an estimated $7.64M.
  • 10x Genomics made up 1.53% of Nikko Asset Management Americas's portfolio in Q1 2026, its #18 holding.
  • Nikko Asset Management Americas first reported a position in 10x Genomics in Q2 2020 and has held it in 24 quarters since.
  • Nikko Asset Management Americas's 10x Genomics position peaked at $299M in Q2 2021.
  • 330 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Nikko Asset Management Americas's 13F filing for Q1 2026, filed 7 May 2026.